NAM logo
  • site map
  • contact
  • advanced search
  • Home
  • News
  • Treatment & Care
  • HIV Worldwide
  • Living with HIV
  • Preventing HIV
  • Organisations
  • HIV Basics
  • About Us
 
Treatment & Care
  • español
  • français
  • português
  • pусский
Starting HIV treatment
  • When to start treatment
    • Choosing a combination
      • Summary: Choosing a combination
      • What to start with
      • Choosing a nucleoside or nucleotide reverse transcriptase inhibitor backbone
      • Choosing a protease inhibitor
      • Choosing a non-nucleoside reverse transcriptase inhibitor
      • Other options
      • Options for simplifying therapy
      • Questions to ask your doctor
    support our work today
    YOU ARE HERE
    • > Home
      • > Treatment & Care
        • > Treatment & Care
          • > Starting HIV treatment

    Choosing a combination

    printer-friendly versionsend to a friendglossarycomment

    Details of how to choose an appropriate treatment combination, including the choice of drugs from each class, newer classes of drugs, and options for simplifying therapy.

    • Summary: Choosing a combination
    • What to start with
    • Choosing a nucleoside or nucleotide reverse transcriptase inhibitor backbone
    • Choosing a protease inhibitor
    • Choosing a non-nucleoside reverse transcriptase inhibitor
    • Other options
    • Options for simplifying therapy
    • Questions to ask your doctor

    latest aidsmap news

    • High rate of death amongst patients with HIV diagnosed late
    • CD4 cell count increases sustained up to five years in developing-world treatment programmes
    • Raltegravir may have role in PEP if exposure involves drug-resistant HIV
    • Excellent outcomes from five years of antiretroviral use in Botswana
    • Study explores verbal and non-verbal communication in unprotected sex between men
    • IL-2 provides quick ‘AIDS rescue’, but effect does not always last
    • Once-a-day etravirine should work as first-line treatment
    • Second-line combinations fail twice as often as first-line ones in the first year
    • If you can't switch, better to stay on failing treatment than stop it, studies show
    • Non-nucleoside resistance is efficiently transmitted within infection ‘clusters’
     
    • Contact NAM
    • Get Email Updates
    • Disclaimer
    • Copyright
    • Developed By NAM